Husain SS, Szabo IL, Tamawski AS (2002) NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action
Double the dose, identical syringe measurement
Vendor reputation matters enormously
Their rapid growth, high fertility, and low incidence of tumors, coupled with their sensitivity to hormonal changes, make them ideal for studying neurological, cardiovascular, and endocrinal disorders
The first completed trial, TRIUMPH-4, reported results in December 2025 showing 28.7% average body weight loss at 68 weeks on the 12mg dose
Lubiprostone (Amitiza) is a prostaglandin E1 analog that stimulates fluid secretion into the intestine by directly and selectively acting on the chloride receptor ClC-2